AVITA Medical, Inc. (FRA:51KA)

Market Cap	124.54M -48.0%
Revenue (ttm)	60.99M +11.5%
Net Income	-41.38M
EPS	-1.49
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	3.620
Previous Close	3.600
Day's Range	3.620 - 3.620
52-Week Range	2.680 - 9.400
Beta	n/a
RSI	59.80
Earnings Date	Feb 12, 2026

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Cary Vance
• Employees: 226
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51KA

Financial Performance

In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.

Financial numbers in USD